MA5-15276

antibody from Invitrogen Antibodies

Targeting: FGF2 FGFB

Provider product page for MA5-15276

Western blot

ELISA

Immunocytochemistry

Immunohistochemistry

Antibody data

Antibody Data
Antigen structure
References [1]
Comments [0]
Validations
Immunocytochemistry [2]
Immunohistochemistry [1]

Submit

Product number: MA5-15276 - Provider product page
Provider: Invitrogen Antibodies
Product name: FGF2 Monoclonal Antibody (2H5G2C11)
Antibody type: Monoclonal
Antigen: Purifed from natural sources
Description: MA5-15276 targets FGF2 in indirect ELISA, IHC and WB applications and shows reactivity with Human samples. The MA5-15276 immunogen is purified recombinant fragment of FGF2 expressed in E. Coli.
Reactivity: Human
Host: Mouse
Isotype: IgG
Antibody clone number: 2H5G2C11
Vial size: 100 µL
Concentration: 1 mg/mL
Storage: Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

FGF2 protein structure - MA5-15276 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescence analysis of FGF2 was performed using 80% confluent log phase BJ and T-47D, control and PTI treated, cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 2% BSA for 45 minutes at room temperature. The cells were labeled with FGF2 Monoclonal Antibody (2H5G2C11) (Product # MA5-15276) at 1:100 in 0.1% BSA, incubated at 4 degree celsius overnight and then labeled with Donkey anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor Plus 488 (Product # A32766), (1:2500 dilution), for 45 minutes at room temperature (Panel a,e,i: Green). Nuclei (Panel b,f,j: Blue) were stained with ProLong™ Diamond Antifade Mountant with DAPI (Product # P36962). F-actin (Panel c,g,k: Red) was stained with Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image of untreated BJ cells showing faint staining for FGF2 that is enhanced upon PTI treatment (Panel h). Panel l represents T-47D cells showing no staining for FGF2 upon PTI treatment. The images were captured at 60X magnification. FGF2 follows type I unconventional secretory pathway where it undergoes self-oligomerization and interacts with the inner and outer leaflets of the plasma membrane for its release. The punctate pattern of FGF2 seen in panel d and h is similar to that shown by Steringer et.al. of the intermediates and oligomers of FGF2 for membrane insertion.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescence analysis of FGF2 was performed using 80% confluent log phase BJ and T-47D, control and PTI treated, cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 2% BSA for 45 minutes at room temperature. The cells were labeled with FGF2 Monoclonal Antibody (2H5G2C11) (Product # MA5-15276) at 1:100 in 0.1% BSA, incubated at 4 degree celsius overnight and then labeled with Donkey anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor Plus 488 (Product # A32766), (1:2500 dilution), for 45 minutes at room temperature (Panel a,e,i: Green). Nuclei (Panel b,f,j: Blue) were stained with ProLong™ Diamond Antifade Mountant with DAPI (Product # P36962). F-actin (Panel c,g,k: Red) was stained with Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image of untreated BJ cells showing faint staining for FGF2 that is enhanced upon PTI treatment (Panel h). Panel l represents T-47D cells showing no staining for FGF2 upon PTI treatment. The images were captured at 60X magnification. FGF2 follows type I unconventional secretory pathway where it undergoes self-oligomerization and interacts with the inner and outer leaflets of the plasma membrane for its release. The punctate pattern of FGF2 seen in panel d and h is similar to that shown by Steringer et.al. of the intermediates and oligomers of FGF2 for membrane insertion.